NCT01636141View on ClinicalTrials.gov

Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Healthy Volunteers
Interventions
DRUG

OLT1177 Gel

OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee

DRUG

Placebo gel

Trial Locations (1)

77845

J&S Studies, Inc, College Station

Sponsors
All Listed Sponsors
lead

Olatec Therapeutics LLC

INDUSTRY